TTD_Target_ID	Target_Name	TTD_Drug_ID	Drug_Name	Drug_Highest_Status	Drug_PubchemID	Molecular_Formula	Molecular_Weight	Canonical_SMILES	Activity	Binder_Type
T76914	Voltage-gated potassium channel Kv1.3	D0QR5G	5-methoxypsoralen	Phase 3	2355	C12H8O4	216.19	COC1=C2C=CC(=O)OC2=CC3=C1C=CO3	IC50 = 101000 nM	Poor binder
T76914	Voltage-gated potassium channel Kv1.3	B2ZOI6	N-[3-(N-(6-Fluoro-1,1-dioxo-1,2-benzothiazol-3-yl)anilino)-2,2-dimethylpropyl]-1-benzofuran-2-carboxamide	Investigative	52949881	C27H24FN3O4S	505.6	CC(C)(CNC(=O)C1=CC2=CC=CC=C2O1)CN(C3=CC=CC=C3)C4=NS(=O)(=O)C5=C4C=CC(=C5)F	IC50 ~ 50000 nM	Poor binder
T76914	Voltage-gated potassium channel Kv1.3	B39OFX	1-[3-(N-(1,1-Dioxo-1,2-benzothiazol-3-yl)anilino)propyl]-3-(4-methylpiperazin-1-yl)urea	Investigative	52946105	C22H28N6O3S	456.6	CN1CCN(CC1)NC(=O)NCCCN(C2=CC=CC=C2)C3=NS(=O)(=O)C4=CC=CC=C43	IC50 ~ 50000 nM	Poor binder
T76914	Voltage-gated potassium channel Kv1.3	B3SO6G	4-(3-Hydroxypiperidin-1-yl)-2,2-diphenylbutanenitrile	Investigative	71459549	C21H24N2O	320.4	C1CC(CN(C1)CCC(C#N)(C2=CC=CC=C2)C3=CC=CC=C3)O	IC50 ~ 100000 nM	Poor binder
T76914	Voltage-gated potassium channel Kv1.3	B5E6XO	N-[3-(N-(6-Fluoro-1,1-dioxo-1,2-benzothiazol-3-yl)anilino)-2,2-dimethylpropyl]-1-methylpiperidine-4-carboxamide	Investigative	52946106	C25H31FN4O3S	486.6	CC(C)(CNC(=O)C1CCN(CC1)C)CN(C2=CC=CC=C2)C3=NS(=O)(=O)C4=C3C=CC(=C4)F	IC50 ~ 50000 nM	Poor binder
T76914	Voltage-gated potassium channel Kv1.3	B6OQM1	1-(3,3-Diphenylpropyl)piperidin-4-ol	Investigative	58282550	C20H25NO	295.4	C1CN(CCC1O)CCC(C2=CC=CC=C2)C3=CC=CC=C3	IC50 = 75000 nM	Poor binder
T76914	Voltage-gated potassium channel Kv1.3	B7G5RD	N'-(1,1-Dioxo-1,2-benzothiazol-3-yl)-N'-phenylpropane-1,3-diamine	Investigative	52947252	C16H17N3O2S	315.4	C1=CC=C(C=C1)N(CCCN)C2=NS(=O)(=O)C3=CC=CC=C32	IC50 ~ 50000 nM	Poor binder
T76914	Voltage-gated potassium channel Kv1.3	B8M3AX	N-[3-(N-(1,1-Dioxo-1,2-benzothiazol-3-yl)anilino)propyl]-3-imidazol-1-ylpropanamide	Investigative	52942845	C22H23N5O3S	437.5	C1=CC=C(C=C1)N(CCCNC(=O)CCN2C=CN=C2)C3=NS(=O)(=O)C4=CC=CC=C43	IC50 ~ 50000 nM	Poor binder
T76914	Voltage-gated potassium channel Kv1.3	B9RJ5C	N-[3-(Benzo[b]thiophen-3-yl-phenyl-amino)-propyl]-4-fluoro-benzamide	Investigative	52949704	C24H21FN2OS	404.5	C1=CC=C(C=C1)N(CCCNC(=O)C2=CC=C(C=C2)F)C3=CSC4=CC=CC=C43	IC50 ~ 50000 nM	Poor binder
T76914	Voltage-gated potassium channel Kv1.3	BAJ3M7	1-[[3-(N-(6-Fluoro-1,1-dioxo-1,2-benzothiazol-3-yl)anilino)-2,2-dimethylpropyl]carbamoyl]cyclopropane-1-carboxylic acid	Investigative	52948768	C23H24FN3O5S	473.5	CC(C)(CNC(=O)C1(CC1)C(=O)O)CN(C2=CC=CC=C2)C3=NS(=O)(=O)C4=C3C=CC(=C4)F	IC50 ~ 50000 nM	Poor binder
T76914	Voltage-gated potassium channel Kv1.3	BDUS15	4-(4-Methoxypiperidin-1-yl)-2,2-diphenylbutanenitrile	Investigative	71457657	C22H26N2O	334.5	COC1CCN(CC1)CCC(C#N)(C2=CC=CC=C2)C3=CC=CC=C3	IC50 ~ 100000 nM	Poor binder
T76914	Voltage-gated potassium channel Kv1.3	BEMB31	N-[3-(N-(6-Fluoro-1,1-dioxo-1,2-benzothiazol-3-yl)anilino)-2,2-dimethylpropyl]-3-hydroxypyridine-4-carboxamide	Investigative	52946322	C24H23FN4O4S	482.5	CC(C)(CNC(=O)C1=C(C=NC=C1)O)CN(C2=CC=CC=C2)C3=NS(=O)(=O)C4=C3C=CC(=C4)F	IC50 ~ 50000 nM	Poor binder
T76914	Voltage-gated potassium channel Kv1.3	BG8KE2	N-{3-[(1,1-Dioxido-1,2-benzothiazol-3-yl)amino]propyl}-4-fluorobenzamide	Investigative	135402606	C17H16FN3O3S	361.4	C1=CC=C2C(=C1)C(=NCCCNC(=O)C3=CC=C(C=C3)F)NS2(=O)=O	IC50 ~ 50000 nM	Poor binder
T76914	Voltage-gated potassium channel Kv1.3	BH7XF5	4-Acetyl-N-[3-(N-(1,1-dioxo-1,2-benzothiazol-3-yl)anilino)propyl]piperazine-1-carboxamide	Investigative	52943618	C23H27N5O4S	469.6	CC(=O)N1CCN(CC1)C(=O)NCCCN(C2=CC=CC=C2)C3=NS(=O)(=O)C4=CC=CC=C43	IC50 ~ 50000 nM	Poor binder
T76914	Voltage-gated potassium channel Kv1.3	BM14NZ	1-(3-Phenylpropyl)piperidin-4-ol	Investigative	21180801	C14H21NO	219.32	C1CN(CCC1O)CCCC2=CC=CC=C2	IC50 ~ 100000 nM	Poor binder
T76914	Voltage-gated potassium channel Kv1.3	BS71WQ	4-(4-Aminopiperidin-1-yl)-2,2-diphenylbutanenitrile	Investigative	71463016	C21H25N3	319.4	C1CN(CCC1N)CCC(C#N)(C2=CC=CC=C2)C3=CC=CC=C3	IC50 ~ 100000 nM	Poor binder
T76914	Voltage-gated potassium channel Kv1.3	BSPX09	N-[3-(4-Cyano-N-(1,1-dioxo-1,2-benzothiazol-3-yl)anilino)propyl]-4-fluorobenzamide	Investigative	52945279	C24H19FN4O3S	462.5	C1=CC=C2C(=C1)C(=NS2(=O)=O)N(CCCNC(=O)C3=CC=C(C=C3)F)C4=CC=C(C=C4)C#N	IC50 ~ 50000 nM	Poor binder
T76914	Voltage-gated potassium channel Kv1.3	BU4TK9	N-[3-(3-Cyano-N-(1,1-dioxo-1,2-benzothiazol-3-yl)anilino)propyl]-4-fluorobenzamide	Investigative	52946269	C24H19FN4O3S	462.5	C1=CC=C2C(=C1)C(=NS2(=O)=O)N(CCCNC(=O)C3=CC=C(C=C3)F)C4=CC=CC(=C4)C#N	IC50 ~ 50000 nM	Poor binder
T76914	Voltage-gated potassium channel Kv1.3	BVPQ90	N-[3-(N-(6-Fluoro-1,1-dioxo-1,2-benzothiazol-3-yl)anilino)-2,2-dimethylpropyl]piperidine-3-carboxamide	Investigative	52942519	C24H29FN4O3S	472.6	CC(C)(CNC(=O)C1CCCNC1)CN(C2=CC=CC=C2)C3=NS(=O)(=O)C4=C3C=CC(=C4)F	IC50 ~ 50000 nM	Poor binder
T76914	Voltage-gated potassium channel Kv1.3	BZ2DO1	4-(N-(1,1-Dioxo-1,2-benzothiazol-3-yl)anilino)butanoic acid	Investigative	52948440	C17H16N2O4S	344.4	C1=CC=C(C=C1)N(CCCC(=O)O)C2=NS(=O)(=O)C3=CC=CC=C32	IC50 ~ 50000 nM	Poor binder